TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02), FiscalAI reports. The company had revenue of $12.88 million during the quarter, compared to the consensus estimate of $14.02 million.
Here are the key takeaways from TriSalus Life Sciences’ conference call:
- Negative sentiment: Third-quarter revenue rose 11% year over year to $12.9 million, but growth was below expectations. TriSalus lowered its 2026 revenue outlook to $46 million–$48 million, or 2%–6% growth, citing slower productivity in new sales territories and a shift toward super-selective Y90 procedures.
- Positive sentiment: FDA clearance of TriNav Advance extends the company’s technology to small distal vessels, addressing procedures it previously could not fully serve. A limited release is underway; management said the product is not included in fourth-quarter revenue guidance.
- Positive sentiment: CMS finalized higher 2027 Medicare payment for Y90 mapping procedures and national pricing of about $13,788 for PEDD procedures in office-based labs. Management expects the changes to strengthen reimbursement and expand access across care settings.
- Positive sentiment: Gross margin improved to 86%, adjusted EBITDA loss narrowed to $4.7 million, and the company ended the quarter with about $41 million in cash, which management said funds its strategic growth plan.
- Neutral sentiment: TriSalus reported 11 active studies across 27 clinical sites and plans to advance comparative studies in liver cancer segments, alongside research in other indications. Upcoming evidence and publications could support adoption, though many milestones remain prospective.
TriSalus Life Sciences Trading Down 11.5%
Shares of TLSI opened at $2.85 on Wednesday. TriSalus Life Sciences has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The business has a 50-day moving average of $4.21 and a 200 day moving average of $4.34. The firm has a market cap of $175.50 million, a P/E ratio of -2.19 and a beta of 0.50. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35.
Key TriSalus Life Sciences News
Here are the key news stories impacting TriSalus Life Sciences this week:
- Positive Sentiment: TriSalus reported third-quarter revenue growth of 11.3% to $12.9 million. Management outlined a 2026 revenue outlook of $46 million to $48 million, while TriNav Advance clearance was cited as a potential growth driver in 2027. Article: TriSalus outlines 2026 revenue outlook and growth drivers
- Neutral Sentiment: A short-interest report stated that short interest totaled zero shares as of November 10, offering no clear indication of notable short-selling pressure. TriSalus Life Sciences stock information
- Negative Sentiment: Quarterly results fell short of consensus: TriSalus reported a loss of $0.15 per share versus the expected $0.13 loss, and revenue of $12.88 million versus estimates of $14.02 million. The revenue shortfall and larger-than-expected loss may weigh on investor sentiment despite year-over-year growth. Article: TriSalus reports third-quarter results
Wall Street Analysts Forecast Growth
TLSI has been the subject of several recent analyst reports. Canaccord Genuity Group set a $4.00 target price on shares of TriSalus Life Sciences in a research note on Tuesday. Wall Street Zen cut shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Research raised shares of TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Citigroup restated a “buy” rating on shares of TriSalus Life Sciences in a research note on Tuesday. Finally, Stifel Nicolaus set a $12.00 target price on TriSalus Life Sciences in a report on Wednesday, September 23rd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.20.
About TriSalus Life Sciences
TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches. Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply. TriSalus offers interventional oncology devices, including the TriNav Infusion System, which is designed to support localized delivery of treatments while helping limit drug diversion away from the targeted tumor.
Read More
- Five stocks we like better than TriSalus Life Sciences
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
- The Trade Desk Beats on Revenue, But the Fine Print Matters
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
